MX2011008060A - Bicyclic amide derivatives for enhancing glutamatergic synaptic responses. - Google Patents

Bicyclic amide derivatives for enhancing glutamatergic synaptic responses.

Info

Publication number
MX2011008060A
MX2011008060A MX2011008060A MX2011008060A MX2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A
Authority
MX
Mexico
Prior art keywords
syndrome
treatment
disorders
compounds
brain
Prior art date
Application number
MX2011008060A
Other languages
Spanish (es)
Inventor
Rudolf Muller
Original Assignee
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharma Inc filed Critical Cortex Pharma Inc
Publication of MX2011008060A publication Critical patent/MX2011008060A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as conditions such as stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
MX2011008060A 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses. MX2011008060A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20664209P 2009-02-02 2009-02-02
PCT/US2010/000255 WO2010087981A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
MX2011008060A true MX2011008060A (en) 2011-09-09

Family

ID=42396261

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008060A MX2011008060A (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses.

Country Status (12)

Country Link
EP (1) EP2391621A4 (en)
JP (1) JP2012516845A (en)
KR (1) KR20110115139A (en)
CN (1) CN102369201A (en)
AU (1) AU2010208646A1 (en)
BR (1) BRPI1005316A2 (en)
CA (1) CA2751285A1 (en)
EA (1) EA018994B1 (en)
IL (1) IL214392A0 (en)
MX (1) MX2011008060A (en)
SG (1) SG173168A1 (en)
WO (2) WO2010087980A2 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450801C (en) * 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
US20020099050A1 (en) * 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
WO1999021422A1 (en) * 1997-10-27 1999-05-06 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
KR101599661B1 (en) * 2007-05-17 2016-03-03 코텍스 파마슈티칼스, 인크. Di-substituted amides for enhancing glutamatergic synaptic responses
US8263591B2 (en) * 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
IL214392A0 (en) 2011-09-27
WO2010087981A2 (en) 2010-08-05
EP2391621A4 (en) 2012-07-25
WO2010087981A3 (en) 2011-03-24
SG173168A1 (en) 2011-08-29
WO2010087980A2 (en) 2010-08-05
WO2010087980A3 (en) 2011-02-24
AU2010208646A1 (en) 2011-09-01
EP2391621A2 (en) 2011-12-07
CA2751285A1 (en) 2010-08-05
CN102369201A (en) 2012-03-07
EA201101162A1 (en) 2012-01-30
BRPI1005316A2 (en) 2019-09-24
JP2012516845A (en) 2012-07-26
EA018994B1 (en) 2013-12-30
KR20110115139A (en) 2011-10-20

Similar Documents

Publication Publication Date Title
MX2009012430A (en) Di-substituted amides for enhancing glutamatergic synaptic responses.
SG163526A1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
MX2010002890A (en) 3-substituted 1,2,3-triazin-4-one&#39;s and 3-substituted 1,3-pyrimidinone&#39;s for enhancing glutamatergic synaptic responses.
TN2009000277A1 (en) 3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses
EA201891374A1 (en) SUBSTITUTED 2-PHENYL-3- (PIPERAZINMETHIL) IMIDAZOPIRIDINES AND THEIR APPLICATION
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
LT2349300T (en) Combination therapy for treatment of patients with neurological disorders and cerebral infarction
MX2009004071A (en) Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto.
EP2318035A4 (en) Methods and compositions for the treatment of symptoms of neurological and mental health disorders
SI2430022T1 (en) 1,2,4-TriazoloŠ4,3-aĆpyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
UA99309C2 (en) Substituted piperidino-dihydrothienopyrimidines
NO20082264L (en) Histamine-3 receptor antagonists
DOP2011000138A (en) NEW COMPOUNDS 578
MX2011011489A (en) Isoxazole-pyridine derivatives.
EP2268140A4 (en) Novel compounds advantageous in the treatment of central nervous system diseases and disorders
MX2011011273A (en) Isoxazole-pyrazole derivatives.
HK1151526A1 (en) Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
SV2009002917A (en) DERIVATIVES OF 3-ALQUILAZETIDINA SUBSTITUTED WITH HETEROCICLES
DE112011101303A5 (en) Two-piece oral telescopic connector for adjustable lower jaw protrusion splint for the treatment of snoring and obstructive sleep apnea
Askenasy Approaching disturbed sleep in late Parkinson's disease: first step toward a proposal for a revised UPDRS
WO2008153958A3 (en) Crystalline forms of (r)-1-{2-[4&#39;- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
MX2011008060A (en) Bicyclic amide derivatives for enhancing glutamatergic synaptic responses.
JP2010529130A5 (en)
HUP0900231A2 (en) Compositions for the treatment of allergic disorders and process for producing them
WO2007061741A3 (en) Modulators of the h3 receptor useful for the treatment of disorders related thereto

Legal Events

Date Code Title Description
FG Grant or registration